Indian stock markets saw a strong upward trend on Wednesday. The Nifty 50 and Sensex both closed higher, driven by gains in auto, FMCG, and...

Cohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...

The Nifty 50 and BSE Sensex rebounded on broad-based buying led by pharma, IT, auto and metals. Volatility eased, while analysts signalled ...

Shares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...

Swiggy, HDFC AMC, Muthoot Finance, and Hero Motocorp are among stocks likely to be upgraded to largecap status in AMFI’s February 2026 resh...

Nuvama Alternative & Quantitative Research anticipates significant shifts in AMFI's upcoming stock reclassification in January 2026. Severa...

Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...

Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...

After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...

Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry po...

JSW Steel's shares rose 4.4% as it incorporated JSW Green Steel Ltd for steel product manufacturing. Its market cap surpassed Rs 2 lakh cro...

Suven Pharmaceuticals and Cohance Lifesciences signed a definitive agreement to merge their businesses, which will further strengthen the f...

Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...

Promoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...

ADIA and HarbourVest are in discussions to acquire a minority stake in Cohance Lifesciences, a pharmaceuticals platform owned by Advent Int...

Advent will also launch an open offer for an additional 26% of the company, a listed contract research and manufacturing services (CRAMS) b...

Post the completion of this acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to...